GENERAL TEXT AMENDMENT
The following amendment has been made to the '2021 RESULT OF ANNUAL GENERAL MEETING' announcement released on 28/06/2021 at 11:03 a.m. under RNS No 3228D.
Update: As at the date of the AGM, the number of issued ordinary shares of the Company was 250,221,297 shares. (Previously read: 250,221,2975 shares).
All other details remain unchanged.
The full amended text is shown below.
28 June 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
2021 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED
ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed.
The results of each resolution were as follows:
| Resolution | For | % For | Against | % Against | Withheld |
| 1. To receive the accounts of the Company for the year ended 31 December 2020 together with the reports thereon of the directors and auditors of the Company | 27,979,197 | 99.93 | 20,000 | 0.07 | 663,319 |
| 2. To re-appoint Dr Stephane Mery as a director of the Company | 22,040,754 | 76.93 | 6,610,683 | 23.07 | 11,079 |
| 3. To re-appoint Nexia Smith & Williams as auditors of the Company | 28,003,061 | 99.92 | 22,348 | 0.08 | 637,107 |
| 4. That the directors be authorised to allot shares on the basis set out in the Notice of Meeting | 27,762,710 | 99.82 | 48,844 | 0.18 | 850,962 |
| 5. To waive pre-emption rights in respect of the issue of the shares on the basis set out in the Notice of Meeting | 27,759,210 | 99.81 | 52,344 | 0.19 | 850,962 |
As at the date of the AGM, the number of issued ordinary shares of the Company was 250,221,297 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.
End
| For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
